go-v.orgdoi

Efficacy and safety of balovaptan for posttraumatic stress disorder: A randomized, placebo-controlled trial.

Sarah Marler, Michael A. Rabbia, Kevin B. Sanders, Michael Derks, Lorna Bailey, Alexandr Vilimovskij, Joerg Maurer, Anna-Lena Nordstroem, Heather Guthrie · Experimental and Clinical Psychopharmacology · 2024

  • DOI 10.1037/pha0000740
  • Publisher American Psychological Association
  • Type article
  • Issued 2024

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Experimental and Clinical Psychopharmacology · American Psychological Association · article · 2024

Abstract

total symptom severity score. No meaningful differences for balovaptan versus placebo were observed at Week 12 for any secondary endpoints. Balovaptan was well tolerated with no new safety findings. The number of participants with at least one adverse event of any intensity was 9/13 (69.2%) in the balovaptan group and 7/16 (43.8%) in the placebo group. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

Open the resolved locator · 10.1037/pha0000740

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:28 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.apa.org/doi/10.1037/pha0000740
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.